D.A. Davidson & CO. Sells 5,428 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

D.A. Davidson & CO. trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 89,158 shares of the company’s stock after selling 5,428 shares during the period. D.A. Davidson & CO.’s holdings in Teva Pharmaceutical Industries were worth $1,494,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC bought a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $39,000. New Age Alpha Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $43,000. Sound Income Strategies LLC grew its stake in shares of Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after buying an additional 2,824 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $74,000. Finally, CWM LLC grew its stake in shares of Teva Pharmaceutical Industries by 18.1% during the second quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after buying an additional 767 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Placid Jover sold 6,053 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Down 0.4%

Shares of Teva Pharmaceutical Industries stock opened at $18.95 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The firm’s 50-day moving average is $19.08 and its two-hundred day moving average is $17.31. The stock has a market cap of $21.73 billion, a price-to-earnings ratio of -118.41, a PEG ratio of 1.04 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.18 billion for the quarter, compared to analysts’ expectations of $4.34 billion. During the same period in the prior year, the business earned $0.61 EPS. The firm’s quarterly revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on TEVA. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Friday. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $25.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.